Rimonabant is a selective cannabinoid receptor type 1 (CB1) antagonist used as a novel anti-obesity agent and smoking cessation aid; it reduces appetite and body weight, decreases waist circumference, and improves metabolic parameters including dyslipidemia, insulin resistance, hyperglycemia, and metabolic syndrome; it also lowers blood pressure, cholesterol, and blood glucose levels, thereby reducing cardiovascular risk factors associated with obesity.